Tranzyme Pharma Names Executive for Discovery Research
Posted June 22, 2006
RESEARCH TRIANGLE PARK, N.C. — Helmut Thomas, a former executive with CIBA-GEIGY and Novartis, is the new senior vice president of research and preclinical development at
Thomas will lead Tranzyme's discovery research and early stage development efforts.
While at Novartis, Thomas led that firm's proof of research in development team for oncology. He also directed preclinical development of more than 25 drug candidates. Thomas received his PhD in biochemistry and organic chemistry from the University of Hannover in Germany.
Tranzyme is focused on treatments for gastrointestinal and metabolic diseases.